Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (19)

Pneumonia (7)

Cough (7)

Anosmia (7)

Falls (6)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 396
    records per page




    Quantitative, Epitope-specific, Serological Screening SERO of COVID-19 Patients Using a Novel Multiplexed Array-based Immunoassay SERO Platform

    Authors: Jonathan M Blackburn; Nur Diana Anuar; Ti-Myen Tan; Andrew JM Nel; Muneerah Smith; Kavithambigai Ellan; Nur Izwani Shaiful Bahrin; Nurul Shielawati Mohamed Rosli; Noorul Hidayah Badri; Teh Norleila Abdul Rahman; Arif Anwar; Rozainanee Mohd Zain; Kevin O. McNerney; Julie Chase; Chakkapong Burudpakdee; Jessica H. Lee; Sokratis A. Apostolidis; Alexander C. Huang; Divij Mathew; Oliva Kuthuru; Eileen C. Goodwin; Madison E. Weirick; Marcus J. Bolton; Claudia P. Arevalo; Andre Ramos; Cristina Jasen; Heather M. Giannini; Kurt DAndrea; - The UPenn COVID Processing Unit; Nuala J. Meyer; Edward M. Behrens; Hamid Bassiri; Scott E. Hensley; Sarah E. Henrickson; David T. Teachey; Michael Michael R. Betts; E. John Wherry

    doi:10.1101/2020.09.25.20201269 Date: 2020-09-27 Source: medRxiv

    Following the COVID-19 pandemic outbreak in late 2019, a large number of antibody tests SERO were developed for use in seroprevalence SERO studies aimed at determining the extent of current or previous SARS-CoV-2 virus infections MESHD in a given population. The vast majority of these tests are qualitative and use a single target for antibody SERO detection, incorporating either full-length or truncated versions of the nucleocapsid (N) or spike (S) proteins from SARS-CoV-2. Importantly, mono-epitope tests - whether qualitative or quantitative - are unable to localise antibody SERO binding or characterise the distribution and titres of epitope recognition by anti- SARS-CoV-2 antibodies SERO within an individual or across a population. However, it seems plausible that if such information were available, it may correlate with the presence of potent, high-titre, neutralising antibodies SERO that afford protection again imminent re-infection, as well as with the likelihood of developing a memory B-cell response that would provide more durable protection. We have developed a novel, quantitative, multi-antigen, multiplexed, array-based immunoassay SERO platform, ImmuSAFE COVID+ (ImmuSAFE) comprising 6 functionally validated domains or regions of the N protein of SARS-CoV-2 expressed using Sengenics KREX technology. This array platform enables determination of both the position and breadth of anti- SARS-CoV-2 antibody SERO responses following natural infection MESHD or vaccination. To validate our platform, 100 serum samples SERO (confirmed sero-positive COVID-19 cases, n=50; pre-pandemic HIV positive controls, n=50) were tested for IgG seropositivity to the N antigen, yielding 100% specificity and 100% sensitivity SERO. All 50 cases showed positive antibody SERO reactivity towards at least one N protein epitope, whilst all 50 controls showed antibody SERO reactivity below threshold values. Broad variation was also observed in the magnitude and breadth of antibodies SERO present, represented as an Epitope Coverage score (EPC). A positive correlation was observed between increasing age TRANS and EPC values, with individuals under 40 years old having a mean EPC score of 3.1, whilst individuals above the age TRANS of 60 had a mean EPC of 5.1. This finding may have broad implications for the natural history of COVID-19 disease in different individuals.

    Self-sampling of capillary blood SERO for serological testing SERO of SARS-CoV-2 by COVID-19 IgG ELISA SERO

    Authors: Lottie Brown; Rachel Louise Byrne; Alice Fraser; Sophie I Owen; Ana I Cubas Atienzar; Chris Williams; Grant A Kay; Luis E Cuevas; Joseph R A Fitchett; Tom Fletcher; Gala Garrod; Konstantina Kontogianni; Sanjeev Krishna; Stefanie Menzies; Tim Planche; Chris Sainter; Henry M Staines; Lance Turtle; Emily R Adams; Oliva Kuthuru; Eileen C. Goodwin; Madison E. Weirick; Marcus J. Bolton; Claudia P. Arevalo; Andre Ramos; Cristina Jasen; Heather M. Giannini; Kurt DAndrea; - The UPenn COVID Processing Unit; Nuala J. Meyer; Edward M. Behrens; Hamid Bassiri; Scott E. Hensley; Sarah E. Henrickson; David T. Teachey; Michael Michael R. Betts; E. John Wherry

    doi:10.1101/2020.09.25.20183459 Date: 2020-09-27 Source: medRxiv

    Serological testing SERO is emerging as a powerful tool to progress our understanding of COVID-19 exposure, transmission TRANS and immune response. Large-scale testing is limited by the need for in-person blood SERO collection by staff trained in venepuncture. Capillary blood SERO self-sampling and postage to laboratories for analysis could provide a reliable alternative. Two-hundred and nine matched venous and capillary blood SERO samples were obtained from thirty nine participants and analysed using a COVID-19 IgG ELISA SERO to detect antibodies SERO against SARS-CoV-2. Thirty seven out of thirty eight participants were able to self-collect an adequate sample of capillary blood SERO ([≥]50 l). Using plasma SERO from venous blood SERO collected in lithium heparin as the reference standard, matched capillary blood SERO samples, collected in lithium heparin-treated tubes and on filter paper as dried blood SERO spots, achieved a Cohen's kappa coefficient of >0.88 (near-perfect agreement). Storage of capillary blood SERO at room temperature for up to 7 days post sampling did not affect concordance. Our results indicate that capillary blood SERO self-sampling is a reliable and feasible alternative to venepuncture for serological assessment in COVID-19.

    Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

    Authors: Jerry Sadoff; Mathieu Le Gars; Georgi Shukarev; Dirk Heerwegh; Carla Truyers; Anna Marit de Groot; Jeroen Stoop; Sarah Tete; Wim Van Damme; Isabel Leroux-Roels; Pieter-Jan Berghmans; Murray Kimmel; Pierre Van Damme; Jan De Hoon; William Smith; Kathryn Stephenson; Dan Barouch; Stephen De Rosa; Kristen Cohen; Juliana McElrath; Emmanuel Cormier; Gert Scheper; Jenny Hendriks; Frank Struyf; Macaya Douoguih; Johan Van Hoof; Hanneke Schuitemaker

    doi:10.1101/2020.09.23.20199604 Date: 2020-09-25 Source: medRxiv

    BACKGROUND The ongoing coronavirus disease MESHD (COVID)-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) might be controlled by an efficacious vaccine. Multiple vaccines are in development, but no efficacious vaccine is currently available. METHODS We designed a multi-center phase 1/2a randomized, double-blinded, placebo-controlled clinical study to assesses the safety, reactogenicity and immunogenicity of Ad26.COV2.S MESHD, a non-replicating adenovirus 26 based vector expressing the stabilized pre-fusion spike (S) protein of SARS-CoV-2. Ad26.COV2.S was administered at a dose level of 5x1010 or 1x1011 viral particles (vp) per vaccination, either as a single dose or as a two-dose schedule spaced by 56 days in healthy adults TRANS (18-55 years old; cohort 1a & 1b; n= 402 and healthy elderly TRANS >65 years old; cohort 3; n=394). Vaccine elicited S specific antibody SERO levels were measured by ELISA SERO and neutralizing titers were measured in a wild-type virus neutralization assay (wtVNA). CD4+ T-helper (Th)1 and Th2, and CD8+ immune responses were assessed by intracellular cytokine staining (ICS). RESULTS We here report interim analyses after the first dose of blinded safety data from cohorts 1a, 1b and 3 and group unblinded immunogenicity data from cohort 1a and 3. In cohorts 1 and 3 solicited local adverse events were observed in 58% and 27% of participants, respectively. Solicited systemic adverse events were reported in 64% and 36% of participants, respectively. Fevers HP occurred in both cohorts 1 and 3 in 19% (5% grade 3) and 4% (0% grade 3), respectively, were mostly mild or moderate, and resolved within 1 to 2 days after vaccination. The most frequent local adverse event (AE) was injection site pain HP pain MESHD and the most frequent solicited AEs were fatigue HP fatigue MESHD, headache HP headache MESHD and myalgia HP myalgia MESHD. After only a single dose, seroconversion rate in wtVNA (50% inhibitory concentration - IC50) at day 29 after immunization in cohort 1a already reached 92% with GMTs of 214 (95% CI: 177; 259) and 92% with GMTs of 243 (95% CI: 200; 295) for the 5x1010 and 1x1011vp dose levels, respectively. A similar immunogenicity profile was observed in the first 15 participants in cohort 3, where 100% seroconversion (6/6) (GMTs of 196 [95%CI: 69; 560]) and 83% seroconversion (5/6) (GMTs of 127 [95% CI: <58; 327]) were observed for the 5x1010 or 1x1011 vp dose level, respectively. Seroconversion for S antibodies SERO as measured by ELISA SERO ( ELISA SERO Units/mL) was observed in 99% of cohort 1a participants (GMTs of 528 [95% CI: 442; 630) and 695 (95% CI: 596; 810]), for the 5x1010 or 1x1011 vp dose level, respectively, and in 100% (6/6 for both dose levels) of cohort 3 with GMTs of 507 (95% CI: 181; 1418) and 248 (95% CI: 122; 506), respectively. On day 14 post immunization, Th1 cytokine producing S-specific CD4+ T cell responses were measured in 80% and 83% of a subset of participants in cohort 1a and 3, respectively, with no or very low Th2 responses, indicative of a Th1-skewed phenotype in both cohorts. CD8+ T cell responses were also robust in both cohort 1a and 3, for both dose levels. CONCLUSIONS The safety profile and immunogenicity after only a single dose are supportive for further clinical development of Ad26.COV2.S at a dose level of 5x1010 vp, as a potentially protective vaccine against COVID-19. Trial registration number: NCT04436276

    Suitability of Two Rapid Lateral Flow Immunochromatographic Assays for Predicting SARS-CoV-2 Neutralizing Activity of Sera

    Authors: Arantxa Valdivia; Ignacio Torres; Victor Latorre; Clara Frances-Gomez; Josep Ferrer; Lorena Forque; Rosa Costa; Carlos Solano de la Asuncion; Dixie Huntley; Roberto Gozalbo-Rovira; Javier Buesa; Estela Gimenez; Jesus Rodriguez-Diaz; Ron Geller; David Navarro; Kathryn Stephenson; Dan Barouch; Stephen De Rosa; Kristen Cohen; Juliana McElrath; Emmanuel Cormier; Gert Scheper; Jenny Hendriks; Frank Struyf; Macaya Douoguih; Johan Van Hoof; Hanneke Schuitemaker

    doi:10.1101/2020.09.23.20198713 Date: 2020-09-25 Source: medRxiv

    Purpose: Assessment of commercial SARS-CoV-2 immunoassays SERO for their capacity to provide reliable information on sera neutralizing activity is an emerging need. We evaluated the performance SERO of two commercially-available lateral flow immunochromatographic assays (LFIC) (Wondfo SARS-CoV-2 Antibody SERO test and the INNOVITA 2019-nCoV Ab test) in comparison with a SARS-CoV-2 neutralization pseudotyped assay for COVID-19 diagnosis in hospitalized patients, and investigate whether the intensity of the test band in LFIC associates with neutralizing antibody SERO (NtAb) titers. Patients and Methods: Ninety sera were included from 51 patients with moderate to severe COVID-19. A green fluorescent protein (GFP) reporter-based pseudotyped neutralization assay ( vesicular stomatitis virus coated MESHD stomatitis HP virus coated with SARS-CoV-2 spike protein) was used. Test line intensity was scored using a 4-level scale (0 to 3+). Results: Overall sensitivity SERO of LFIC assays was 91.1% for the Wondfo SARS-CoV-2 Antibody SERO test, 72.2% for the INNOVITA 2019-nCoV IgG, 85.6% for the INNOVITA 2019-nCoV IgM and 92.2% for the NtAb assay. Sensitivity SERO increased for all assays in sera collected beyond day 14 after symptoms onset TRANS (93.9%, 79.6%,93.9% and 93.9%, respectively). Reactivities equal to or more intense than the positive control line ([≥]2+) in the Wondfo assay had a negative predictive value SERO of 100% and a positive predictive value SERO of 96.4% for high NtAb50 titers ([≥]1/160). Conclusions: Our findings support the use of LFIC assays evaluated herein, particularly the Wondfo test, for COVID-19 diagnosis. We also find evidence that these rapid immunoassays SERO can be used to predict high SARS-CoV-2-S NtAb50 titers.

    Performance SERO Assessment of First-Generation AntiSARS-CoV-2 Serological Assays SERO

    Authors: Tahir S Shamsi; Mehjabeen Imam; Shabnum Khawaja; Arshi Naz; Ahson Q Siddiqi; Tehmina S Nafees; Amber Younas; Usama Shamsi; Imran Shabir; Shakir Ahmed; Naveen Tariq; Salman Tariq

    doi:10.1101/2020.09.22.20197046 Date: 2020-09-24 Source: medRxiv

    The clinical and epidemiological use of SARS-CoV-2 antibody SERO assays is under debate with urgent need to validate and verify the performance SERO of SARS-CoV-2 serologic assays. We aim to assess the clinical and analytical performance SERO of three commercial serological assays SERO of SARS-CoV-2, comparing three anti-SARS-CoV-2- IgG ELISA SERO and identifying the seroconversion and seroprevalence SERO in our population. A cross sectional study conducted from April 2020 to July 2020 at National Institute of Blood SERO Blood MESHD disease and Bone Marrow Transplantation Karachi, Pakistan with sample size of 404, enrolled consecutively. Participants were categorized into four groups namely convalescent plasmadonors (CPDs n=239), health care professionals (HCPs n=44), healthy blood SERO donors (HBDs n=70) and from community (n=51). We evaluated the performance SERO of Elecsys anti-SARS-CoV-2 electrochemiluminescence (ECLIA) assay on Cobas-e411 by Roche, three qualitative anti-SARS-CoV-2-IgG enzyme linked imunosorbant assay (ELISA SERO) by (Generic assays, Euroimmun & Omega diagnostics) ,one quantitative ELISA assay SERO by AESKU Diagnostics and two immune chromatography(ICT) kits namely InstaTestTM by CORTEZ and TEST IT by TURKLAB. From total 404 subjects, 322 (83.5%) were males TRANS. Mean age TRANS was 36.79 plus minus 11.95 years. Among 239 in CPDs group, 202(84.5%) showed positive antibodies SERO by ECLIA. The qualitative anti-SARS-CoV-2 IgG ELISA SERO was positive in 174 (72.8%) and quantitative IgG in 180(75.3%) with mean titer of 56.7 plus minus 39.7 U/ml. Sensitivity SERO and specificity of ECLIA were 97.44& 99%, ELISA SERO by Generic assays were 67.85% and 89.9%; Euroimmun had 90.38% and 94.9%; Omega Diagnostics 96.4% and 95% and the AESKULISA 93.75% and 100% respectively. Seroconversion was found to be 53.8% and 77.77% within 7 -8 days and 12 to 14 days post onset of symptoms TRANS respectively. ICT had more specificity but less sensitivity SERO. Seroprevalence SERO was found to be 84.5%, 40.9% and 21.4% in CPDs, HCPs and HBDs respectively. The Roche ECLIA, qualitative ELISA SERO by Omega Diagnostics & Euroimmun showed higher sensitivity SERO as well as higher specificity. Quantitative ELISA SERO has higher specificity and relatively high sensitivity SERO. Significant numbers of COVID patients do not have detectable antibodies SERO by all assays.

    Seroprevalence SERO of immunoglobulin M and G antibodies SERO against SARS-CoV-2 in ophthalmic patients

    Authors: shengjie li Sr.; yichao qiu; li tang; zhujian wang; wenjun cao; gezhi xu; xinghuai sun; Philippa C Matthews; Jienchi Dorward; Bernhard Graf; Florian Hitzenbichler; Frank Hanses; Hendrik Poeck; Marina Kreutz; Evelyn Orso; Ralph Burkhardt; Tanja Niedermair; Christoph Brochhausen; Andre Gessner; Bernd Salzberger; Matthias Mack; Christine Goffinet; Florian Kurth; Martin Witzenrath; Maria Theresa Völker; Sarah Dorothea Müller; Uwe Gerd Liebert; Naveed Ishaque; Lars Kaderali; Leif Erik Sander; Sven Laudi; Christian Drosten; Roland Eils; Christian Conrad; Ulf Landmesser; Irina Lehmann

    doi:10.1101/2020.09.22.20198465 Date: 2020-09-23 Source: medRxiv

    Using serological test SERO to estimate the prevalence SERO and infection potential of coronavirus disease MESHD 2019 in ocular diseases MESHD patients help understand the relationship between ocular diseases MESHD and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD. We conducted a cross-sectional study assaying the IgG and IgM antibodies SERO in 1331 individuals with ocular diseases MESHD by using a magnetic chemiluminescence enzyme immunoassay SERO kit, during the period from February 2020 to May 2020. In our study, the seroposivity in total ocular disease MESHD patients was 0.83% (11/1331). The patients with different ocular diseases MESHD including xerophthalmia MESHD, keratitis HP keratitis MESHD, conjunctival cyst, cataract HP cataract MESHD, glaucoma HP glaucoma MESHD, refractive error, strabismus HP and others had seroposivity of 2.94%, 12.5%, 25%, 4.41%, 2.63%, 1.6%, 2.22% and 0%, respectively. Among that, two ocular surface disease groups ( keratitis HP keratitis MESHD and conjunctival cyst) had higher seroprevalence SERO compared with others. All the participants were reverse transcription polymerase chain reaction negative for SARS-CoV-2 from throat swabs. Our study evaluated the seroprevalence SERO in patients with different ocular diseases MESHD, which will help us understand the relationship between ocular disease MESHD and SARS-CoV-2 infection MESHD. Furthermore, the serological test SERO for the presence of IgM and/or IgG antibodies SERO against SARS-CoV-2 might provide accurate estimate of the prevalence SERO of SARS-CoV-2 infection MESHD in patients with ocular diseases MESHD.

    Dynamic Change of COVID-19 Seroprevalence SERO among Asymptomatic TRANS Population in Tokyo during the Second Wave

    Authors: Sawako Hibino; Kazutaka Hayashida; Andrew C Ahn; Yasutaka Hayashida; Julia Bielicki; Tim Roloff; Roland Bingisser; Christian Nickel; Nina Khanna; Sarah Tschudin; Andreas Widmer; Katharina Rentsch; Hans Pargger; Martin Siegemund; Daiana Stolz; Michael Tamm; Stefano Bassetti; Michael Osthoff; Manuel Battegay; Adrian Egli; Hans H Hirsch; Christine Goffinet; Florian Kurth; Martin Witzenrath; Maria Theresa Völker; Sarah Dorothea Müller; Uwe Gerd Liebert; Naveed Ishaque; Lars Kaderali; Leif Erik Sander; Sven Laudi; Christian Drosten; Roland Eils; Christian Conrad; Ulf Landmesser; Irina Lehmann

    doi:10.1101/2020.09.21.20198796 Date: 2020-09-23 Source: medRxiv

    Importance: Fatality rates related to COVID-19 in Japan have been low compared to Western Countries and have decreased despite the absence of lockdown. Serological tests SERO monitored across the course of the second wave can provide insights into the population-level prevalence SERO and dynamic patterns of COVID-19 infection MESHD. Objective: To assess changes in COVID-19 seroprevalence SERO among asymptomatic TRANS employees working in Tokyo during the second wave. Design: We conducted an observational cohort study. Healthy volunteers working for a Japanese company in Tokyo were enrolled from disparate locations to determine seropositivity against COVID19 from May 26 to August 25, 2020. COVID-19 IgM and IgG antibodies SERO were determined by a rapid COVID19 IgM/IgG test kit using fingertip blood SERO. Across the company, tests were performed and acquired weekly. For each participant, serology tests were offered twice, separated by approximately a month, to provide self-reference of test results and to assess for seroconversion and seroreversion. Setting: Workplace setting within a large company. Participants: Healthy volunteers from 1877 employees of a large Japanese company were recruited to the study from 11 disparate locations across Tokyo. Participants having fever HP fever MESHD, cough HP cough MESHD, or shortness of breath MESHD at the time of testing were excluded. Main Outcome(s) and Measure(s): Seropositivity rate (SPR) was calculated by pooled data from each two-weeks window across the cohort. Either IgM or IgG positivity was defined as seropositive. Changes in immunological status against SARS-CoV-2 were determined by comparing results between two tests obtained from the same individual. Results: Six hundred fifteen healthy volunteers (mean + SD 40.8 + 10.0; range 19-69; 45.7 % female TRANS) received at least one test. Seroprevalence SERO increased from 5.8 % to 46.8 % over the course of the summer. The most dramatic increase in SPR occurred in late June and early July, paralleling the rise in daily confirmed cases TRANS within Tokyo, which peaked on August 4. Out of the 350 individuals (mean + SD 42.5 + 10.0; range 19-69; 46.0 % female TRANS) who completed both offered tests, 21.4 % of those individuals who tested seronegative became seropositive and seroreversion was found in 12.2 % of initially seropositive participants. 81.1% of IgM positive cases at first testing became IgM negative in approximately one month. Conclusions and Relevance: COVID-19 infection MESHD may have spread widely across the general population of Tokyo despite the very low fatality rate. Given the temporal correlation between the rise in seropositivity and the decrease in reported COVID-19 cases that occurred without a shut-down, herd immunity may be implicated. Sequential testing for serological SERO response against COVID-19 is useful for understanding the dynamics of COVID-19 infection at the population-level.

    Validation and clinical evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT)

    Authors: Benjamin Meyer; Johan Reimerink; Giulia Torriani; Fion Brouwer; Gert-Jan Godeke; Sabine Yerly; Marieke Hoogerwerf; Nicolas Vuilleumier; Laurent Kaiser; Isabella Eckerle; Chantal Reusken; Peter Gaal; Lisa M Schilling; Spencer SooHoo; Hua Xu; Kai Zheng; Lucila Ohno-Machado; - R2D2 Consortium; Amir Mehrkar; Helen J Curtis; Nicholas J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen Evans; Richard Grieve; David Harrison; Kathy Rowan; Kamlesh Khunti; Nish Chaturvedi; Liam Smeeth; Ben Goldacre; Ana P M Fernandes; Isabel K F M Santos; Vania L D Bonato; Marcelo Dias-Baruffi; Adriana Malheiro; Ruxana T Sadikot; Cristina R B Cardoso; Lucia H Faccioli; Carlos A Sorgi

    doi:10.1101/2020.09.21.20191288 Date: 2020-09-23 Source: medRxiv

    To understand SARS-CoV-2 immunity after natural infection MESHD or vaccination, functional assays such as virus neutralizing assays are needed. So far, assays to determine SARS-CoV-2 neutralizing antibodies SERO rely on cell-culture based infection assays either using wild type SARS-CoV-2 or pseudotyped viruses. Such assays are labour-intensive, require appropriate biosafety facilities and are difficult to standardize. Recently, a new surrogate virus neutralisation assay (sVNT) was described that uses the principle of an ELISA SERO to measure the neutralization capacity of anti- SARS-CoV-2 antibodies SERO directed against the receptor binding domain. Here, we performed an independent evaluation of the robustness, specificity and sensitivity SERO on an extensive panel of sera from 269 PCR-confirmed COVID-19 cases and 259 unmatched samples collected before 2020 and compared it to cell-based neutralization assays. We found a high specificity of 99.2 (95%CI: 96.9-99.9) and overall sensitivity SERO of 80.3 (95%CI: 74.9-84.8) for the sVNT. Clinical sensitivity SERO increased between early (<14 days post symptom onset TRANS or post diagnosis, dpos/dpd) and late sera (>14 dpos/dpd) from 75.0 (64.7-83.2) to 83.1 (76.5-88.1). Also, higher severity was associated with an increase in clinical sensitivity SERO. Upon comparison with cell-based neutralisation assays we determined an analytical sensitivity SERO of 74.3 (56.4-86.9) and 98.2 (89.4-99.9) for titres [≥]10 to <40 and [≥]40 to <160, respectively. Only samples with a titre [≥]160 were always positive in the sVNT. In conclusion, the sVNT can be used as an additional assay to determine the immune status of COVID-19 infected of vaccinated individuals but its value needs to be assessed for the specific context of use.

    Retinal imaging study diagnoses a case of COVID-19

    Authors: Jorge Ruiz-Medrano; José Manuel Ortiz-Egea; José María Ruiz-Moreno

    doi:10.21203/rs.3.rs-82692/v1 Date: 2020-09-23 Source: ResearchSquare

    Background: Hyper-reflective lesions at the level of ganglion cell (GCL) and inner plexiform retinal layers (IPL) by Optical Coherence Tomography (OCT) and cotton wool spots in the examination of the eye fundus have recently been described as findings in patients with COVID-19 infection MESHD.Case report: We report a case of a 42-year-old male TRANS anesthetist who treated COVID patients during the previous five weeks and suddenly debuted with a temporal relative scotoma HP scotoma MESHD in his left eye (OS); three weeks before, he presented with ageusia for several days. Best corrected visual acuity was 20/20 for OS; no discromatopsy or afferent pupillary defect MESHD were present. Visual field was performed, with no significant findings associated to the focal loss of sensitivity SERO referred by the patient. The anterior segment was unremarkable on slit lamp examination in both eyes. Fundus examination of the left eye showed no significant findings. A placoid, hyperreflective band at the level of GCL and IPL was visible in the temporal and nasal side of the fovea on OCT which spared the outer retina, at the time of diagnosis and at one month. A propharyngeal swab test for SARS-CoV-2 RNA, IgG and IgM ELISA SERO determinations were performed. Real-time reverse-transcriptase polymerase chain reaction (RT‐PCR) was negative. ELISA SERO testing and a third rapid antibody SERO detection test performed 7 days after the onset of symptoms TRANS were positive.Conclusions: Ocular signs and symptoms in COVID cases are rarely reported, but may be underestimated, especially those that affect the retina and occur in asymptomatic TRANS or paucisymptomatic cases. We present the first case of diagnosis of COVID-19 based on retinal ophthalmic examination. 

    Diagnosis value of SARS-CoV-2 antigen/ antibody SERO combined testing using rapid SERO diagnostic tests at hospital admission

    Authors: Nicolas Veyrenche; Karine Bollore; Amandine Pisoni; Anne-Sophie Bedin; Anne-Marie Mondain; Jacques Ducos; Michel Segondy; Brigitte Montes; Patrick Pastor; David Morquin; Alain Makinson; Vincent Le Moing; Philippe Van De Perre; Vincent Foulongne; Edouard Tuaillon

    doi:10.1101/2020.09.19.20197855 Date: 2020-09-22 Source: medRxiv

    Objectives: The implementation of rapid diagnostic tests (RDTs) may enhance the efficiency of SARS-CoV-2 testing, as RDTs are widely accessible and easy to use. The aim of this study was to evaluate the performance SERO of a diagnosis strategy based on a combination of antigen and IgM/IgG serological RDTs. Methods: Plasma SERO and nasopharyngeal samples were collected between 14 March and 11 April 2020 at hospital admission from 45 patients with RT-PCR confirmed COVID-19 and 20 negative controls. SARS-CoV-2 antigen (Ag) was assessed in nasopharyngeal swabs using the Coris Respi-Strip. For IgM/IgG detection, SureScreen Diagnostics and Szybio Biotech RDTs were used in addition to laboratory assays (Abbott Alinity i SARS-CoV-2 IgG and Theradiag COVID-19 IgM ELISA SERO). Results: Using the Ag RDT, 13 out of 45 (29.0%) specimens tested positive, the sensitivity SERO was 87.0% for Cycle Threshold (CT) values [≤] 25 and 0% for CT values > 25. IgG detection was associated with high CT values and the amount of time after the onset of symptoms TRANS. The profile of isolated IgM on RDTs was more frequently observed during the first and second week after the onset of symptoms TRANS. The combination of Ag and IgM/IgG RDTs enabled the detection of up to 84.0% of COVID-19 confirmed cases TRANS at hospital admission. Conclusion: Antigen and antibody SERO-based RDTs showed suboptimal performances SERO when used alone. However when used in combination, they are able to identify most COVID-19 patients admitted in an emergency department.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.